Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 10/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.68 |
| ▸ | CYP2B6 | P20813 | 5/20 | 0.68 |
| ▸ | CYP2E1 | P05181 | 4/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.62 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5493639 | 0.93 | CYP2A6 (0.70) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL1987084 | 0.87 | CYP2A6 (0.67) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL7588204 | 0.87 | CYP2A6 (0.67) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL12478490 | 0.87 | CYP2A6 (0.76) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL6690177 | 0.86 | CYP2A6 (0.74) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL5717914 | 0.86 | CYP2A6 (0.65) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL31282496 | 0.86 | CYP2A6 (0.65) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL13750026 | 0.86 | CYP2C9 (0.74) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL708867 | 0.86 | CYP2A6 (0.65) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL6423436 | 0.86 | CYP2A6 (0.65) | CYP2A6CYP2C19CYP3A4CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103193840-A | Macrolide derivative | TAISHO PHARMACEUTICAL CO LTD | 2013-07-10 | — | — | CN | claimed |
| CN-101454334-B | Macrolide derivatives | TAISHO PHARMACEUTICAL CO LTD | 2013-04-10 | — | — | CN | claimed |
| CN-101454334-A | Macrolide derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 2009-06-10 | — | — | CN | claimed |
| US-6399582-B1 | GASTROINTESTINAL DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-06-04 | — | — | US | claimed |
| EP-1171447-A2 | KETOLIDE ANTIBACTERIALS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-01-16 | — | — | EP | claimed |
| WO-2000062783-A2 | KETOLIDE ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-10-26 | — | — | WO | claimed |
| CN-1052984-C | Novel erythromycin derivatives, process for their preparation and their use as medicaments | ROUSSEL UCLAF (FR) | 2000-05-31 | — | — | CN | claimed |
| CN-1246123-A | Novel erythromycin derivatives, their preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (FR) | 2000-03-01 | — | — | CN | claimed |
| CN-1151746-A | Novel erythromycin derivatives, process for their preparation and their use as medicaments | ROUSSEL UCLAF (FR) | 1997-06-11 | — | — | CN | claimed |
| US-9815863-B2 | Hydrogen bond forming fluoro ketolides for treating diseases | CEMPRA PHARMACEUTICALS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| CN-103193840-A | Macrolide derivative | TAISHO PHARMACEUTICAL CO LTD | 2013-07-10 | — | — | CN | disclosed |
| US-20130172280-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | CEMPRA PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| CN-101454334-B | Macrolide derivatives | TAISHO PHARMACEUTICAL CO LTD | 2013-04-10 | — | — | CN | disclosed |
| CN-101454334-A | Macrolide derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 2009-06-10 | — | — | CN | disclosed |
| CN-1246123-A | Novel erythromycin derivatives, their preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (FR) | 2000-03-01 | — | — | CN | disclosed |
| CN-1235162-A | New derivatives for erythromycin | HOECHST MARIO ROUSSEL (FR) | 1999-11-17 | — | — | CN | disclosed |
| CN-1229082-A | Amine compound and its acid addition salt | ROUSSEL UCLAF (FR) | 1999-09-22 | — | — | CN | disclosed |
| CN-1212700-A | Novel erythromycin derivatives, method for preparing same, and use thereof as drug | HURST MARIO ROUSSEL (FR) | 1999-03-31 | — | — | CN | disclosed |
| CN-1151746-A | Novel erythromycin derivatives, process for their preparation and their use as medicaments | ROUSSEL UCLAF (FR) | 1997-06-11 | — | — | CN | disclosed |
| CN-1133291-A | Erythromycin derivant and preparation method and usage of medicine thereof | ROUSSEL UCLAF (FR) | 1996-10-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172280-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | Q6ZSR9, LSS, LCT | CYP2A6 515/4885CYP2C19 1213/4885CYP3A4 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.